Skip to content

Rivaroxaban Monotherapy and CYP2C19 Genotype Testing in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-508904-39-00
Enrollment
50
Registered
2024-03-18
Start date
2024-08-22
Completion date
Unknown
Last updated
2024-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease, Percutaneous coronary intervention, Atrial fibrillation

Brief summary

The primary ischemic endpoints at 6 months is the composite of all-cause mortality, myocardial infarction (according to the 4th universal definition of MI), Academic Research Consortium (ARC) defined definite stent thrombosis, or ischemic stroke, The primary bleeding endpoint at 6 months is major bleeding or clinically relevant non-major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria

Interventions

Sponsors

Amsterdam UMC
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary ischemic endpoints at 6 months is the composite of all-cause mortality, myocardial infarction (according to the 4th universal definition of MI), Academic Research Consortium (ARC) defined definite stent thrombosis, or ischemic stroke, The primary bleeding endpoint at 6 months is major bleeding or clinically relevant non-major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026